Compare ALLT & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | RZLT |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.0M | 420.8M |
| IPO Year | 2006 | 2011 |
| Metric | ALLT | RZLT |
|---|---|---|
| Price | $7.73 | $4.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $12.40 | $9.67 |
| AVG Volume (30 Days) | 243.1K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.84 | N/A |
| Revenue Next Year | $12.09 | N/A |
| P/E Ratio | $469.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.12 | $1.07 |
| 52 Week High | $11.92 | $11.46 |
| Indicator | ALLT | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 48.16 |
| Support Level | $7.41 | $4.51 |
| Resistance Level | $8.51 | $4.71 |
| Average True Range (ATR) | 0.37 | 0.26 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 28.92 | 27.78 |
Allot Ltd is a provider of security and network intelligence solutions for mobile, fixed, and cloud service providers, as well as enterprises. It offers network-based security solutions such as mobile security, DDoS protection, and IoT security, along with network analytics and traffic management. It focuses on expanding its Security-as-a-Service (SECaaS) offerings through the Allot Secure product family, which delivers unified protection for consumers and SMBs across mobile, fixed, and 5G networks. Its Allot Smart solutions enable service providers to analyze and manage network data, optimize performance, reduce costs, and enhance user experience. It has a customer base in Europe, which generates maximum revenue, as well as in Asia and Oceania, the Americas, the Middle East, and Africa.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.